nirsevimab is a preventive monoclonal antibody approved in Europe in late 2022. It is the leading cause of paediatric hospitalisation in Europe. In France, bronchiolitis is estimated to affect nearly 30% of newborns under two years old every year.
#HEALTH #English #TZ
Read more at Euronews